Amgen Wins Injunction To Block Apotex Biosimilar
This article was originally published in Scrip
Executive Summary
A Florida district court has imposed a preliminary injunction that would block Apotex Corp. from marketing its pegfilgrastim biosimilar of Amgen Inc.'s long-acting human granulocyte colony-stimulating factor Neulasta for at least six months after the medicine gains the FDA's approval.